Encouraging results reported for injectable flu drug

first_img Sheridan said no significant differences in any of the efficacy end points were seen, which “was expected given the active control, small sample size, and exploratory phase 2 nature of this study.” Oct 28 news release about outpatient studyhttp://investor.shareholder.com/biocryst/ReleaseDetail.cfm?ReleaseID=343466 In the other trial, hospital patients who were seriously ill with flu were treated for 5 days with either IV peramivir or oseltamivir, with similar results in both groups, including no deaths and a median of 4.0 days to hospital discharge, the company said. Oct 27 news release about hospital studyhttp://investor.shareholder.com/biocryst/ReleaseDetail.cfm?ReleaseID=343132 Clinical stability was a composite measure based on temperature, oxygen saturation, respiratory rate, systolic blood pressure, and heart rate. For ethical reasons, the study included no placebo arm. In addition, both peramivir groups had significant improvements in a composite symptoms score, starting as early as 24 hours after treatment, the statement said. The drug was well-tolerated, with adverse-event profiles similar for the treatment and placebo groups. Hospital studyThe inpatient study was designed primarily to assess how long it would take patients with serious or life-threatening flu to become clinically stable with 5 days of treatment with peramivir or oseltamivir. The study was conducted at centers in the United States, Canada, Hong Kong, Singapore, Australia, New Zealand, and South Africa. “This phase 2 study was a critical test of peramivir, which demonstrated for the first time that a single administration of this potent neuraminidase inhibitor can be effective in treating seasonal influenza,” Dr. William P. Sheridan, chief medical officer of BioCryst, said in the news release. Secondary outcomes for all groups included no mortality, no clinical relapse, a median of 4.0 days to hospital discharge, and a median of 10.8 days to resumption of normal activities, the company reported. Sep 20, 2007, CIDRAP News story “Trial of injectable flu drug yields disappointing results” Sheridan also said that the zero mortality in the study is “an important finding worthy of follow-up,” given that a previous epidemiologic study showed a mortality rate of 10% in 219 patients who were not treated with neuraminidase inhibitors. See also: Page with link to recording of Oct 27 BioCryst teleconference (free registration required)http://investor.shareholder.com/biocryst/eventdetail.cfm?eventid=60565 Peramivir is a neuraminidase inhibitor, like the licensed antivirals oseltamivir (Tamiflu), which is taken orally, and zanamivir (Relenza), inhaled as a powder. In response to questions, he said the study was not designed to show differences between peramivir and oseltamivir. He said peramivir is important because it permits parenteral treatment of flu patients, adding, “At the ICAAC meeting the need for a parenteral drug for influenza has come up several times already. Also there’s concern about resistance to existing drugs, including oseltamivir.” The primary end point was time to alleviation of symptoms, which was 81.8 hours for the placebo group. The respective times for the 300-mg and 600-mg peramivir groups were 59.1 and 59.9 hours, both of which were significant reductions, the company said. Oct 31, 2008 (CIDRAP News) – BioCryst Pharmaceuticals Inc. reported encouraging results this week in two phase 2 trials of its injectable antiviral drug, peramivir, a potential new treatment for influenza. In one study, a single intravenous (IV) dose of peramivir in outpatients ill with flu reduced the duration of their symptoms by about 22 hours compared with a placebo group, a statistically significant difference, according to BioCryst, based in Birmingham, Ala. Neither set of results has yet been published in a peer-reviewed journal. The company described the inpatient study in a press release and a teleconference on Oct 27; the outpatient study was reported in an Oct 28 press release and a poster presentation at the 46th Interscience Conference on Antimicrobials and Chemotherapy/Infectious Diseases Society of America (ICAAC/IDSA) meeting this week in Washington, DC. Outpatient findingsThe outpatient study was sponsored and conducted in Japan by Shionogi & Co. Ltd., which in 2007 bought from BioCryst the rights to develop and market peramivir in Japan. “The time to clinical stability was 25.3 hours for all groups combined, with no statistically significant differences across treatment groups,” Sheridan reported during the Oct 27 conference call (a recording of which is available online). In the news release, Dr. Michael Ison of Northwestern University, principal investigator in the study, said, “This landmark study provides us great insight into the course of treatment for patients who are hospitalized for influenza. The results indicate a potential role for antiviral therapy, which is critical as currently there are no antivirals approved for patients hospitalized for acute serious or potentially life-threatening influenza.” The new findings come 13 months after the company reported disappointing results in an earlier phase 2 trial of the drug. In that study, flu patients who received injections of peramivir did better than a placebo group, but the difference was not significant. The company said at the time that the use of shorter needles than were used in an earlier trial probably resulted in inadequate doses. The study involved 296 patients who tested positive for influenza within 48 hours after symptom onset, BioCryst reported. The volunteers were divided into three groups, with 99 receiving 300 milligrams (mg) of peramivir IV, 97 receiving 600 mg of the drug IV, and 100 receiving an IV placebo. The investigators enrolled 122 patients who had flu confirmed by polymerase chain reaction. Of these, 41 received 75 mg of oseltamivir twice daily, 41 received 200 mg of IV peramivir twice daily, and 40 received 400 mg of IV peramivir twice daily.last_img read more

HEP put into operation the 100th charging station for electric vehicles

first_imgPhoto: Pixabay.com See a list of all ELEN electric chargers HERE. You can also see the locations of the Tesla chargers HERE. At the moment, HEP’s filling station network covers all motorways and other important road routes in Croatia, city centers and tourist destinations, including several islands, and covers the area of ​​the City of Zagreb and 18 counties. At the beginning of 2015, HEP started the cycle of construction of ELEN filling stations in Croatian cities following the items of Directive 2014/94 / EU on the establishment of infrastructure for alternative fuels, which by 2020 provides for the availability of filling stations every 50 kilometers of motorways in all agglomerations with more than 20.000 inhabitants, in all sea, air and inland ports, as well as at railway and bus stations.center_img “With the commissioning of the 26th charging station for electric vehicles, Hrvatska elektroprivreda confirms itself as a key entity in the electrification of traffic in Croatia, which we carry out in accordance with the guidelines of the Government of the Republic of Croatia and the policies of the European Union. At the moment, in the realization and plans, we have the installation of more than a hundred bottling plants throughout Croatia, of which XNUMX in Zagreb”, said the President of the Management Board of Hrvatska elektroprivreda Frane Barbarić and added that HEP is only halfway through the planned construction of infrastructure for electric vehicles, with a total value of 60 million kuna. In Zagreb, HEP put into operation the jubilee hundredth charging station for electric vehicles, which, after the opening of charging stations on Croatian motorways, continued the expansion of the ELEN network in cities in order to enable safe intercity driving by electric car throughout the country. last_img read more

Arsenal manager Unai Emery reacts to Jose Mourinho replacing Mauricio Pochettino at Tottenham

first_imgArsenal manager Unai Emery reacts to Jose Mourinho replacing Mauricio Pochettino at Tottenham Advertisement Advertisement Unai Emery has reacted after Tottenham replaced Mauricio Pochettino with Jose Mourinho (Pictures: Getty)Arsenal manager Unai Emery admits he was ‘surprised’ Tottenham decided to part ways with Mauricio Pochettino and move for Jose Mourinho.Spurs have endured a miserable start to the 2019-20 campaign but reached the Champions League final under Pochettino last season.Despite this, Daniel Levy opted to sack Pochettino on Tuesday evening and Tottenham subsequently confirmed Mourinho – the former Manchester United, Chelsea and Real Madrid boss – had taken over the club. Metro Sport ReporterThursday 21 Nov 2019 2:10 pmShare this article via facebookShare this article via twitterShare this article via messengerShare this with Share this article via emailShare this article via flipboardCopy link1.8kShares Comment Spurs sacked Mauricio Pochettino on Tuesday (Picture: Getty)Reacting to the change in management at Spurs, Arsenal boss Emery said: ‘I think it’s a surprise how it finished with Pochettino.ADVERTISEMENT‘I don’t know exactly why and how it’s going to change their performance.AdvertisementAdvertisement‘[Jose] is a very good coach, his career is strong with titles and experience and I think also Pochettino working in Tottenham was amazing.’Asked whether he was surprised by Pochettino’s sacking, Emery said: ‘Yes, for me it was a surprise.More: FootballRio Ferdinand urges Ole Gunnar Solskjaer to drop Manchester United starChelsea defender Fikayo Tomori reveals why he made U-turn over transfer deadline day moveMikel Arteta rates Thomas Partey’s chances of making his Arsenal debut vs Man City‘Maybe the last matches they didn’t achieve a good result but in the last year with Pochetinno was perfect.‘They decided to change and I don’t know the reason but we have our way and they have their way. We want to keep that distance [ahead of them in the Premier League table].’Mourinho’s Tottenham face London rivals West Ham on Saturday while Arsenal welcome Southampton to the Emirates.MORE: Jose Mourinho pays tribute to Mauricio Pochettino during first Tottenham press conferencelast_img read more

Arsenal defender Cedric Soares issues fitness update

first_imgWorking hard with the guys and getting closer to full fitness. 🔴🔝💪🏼 #work #training #COYG #EPL #team #Arsenal pic.twitter.com/sLfICQ21yj— Cédric Soares (@OficialCedric) March 6, 2020 Comment Coral BarryFriday 6 Mar 2020 9:57 pmShare this article via facebookShare this article via twitterShare this article via messengerShare this with Share this article via emailShare this article via flipboardCopy link8.3kShares Arsenal are hopeful Soares will return to full training next week (Picture: Getty)‘Financially the impact is enormous because the structure of this club is built to be in the Champions League and you can sustain that for one year or two, but then after you have to start making decisions.‘So we will have to make decisions one way or the other depending on the scenario we find ourselves in, whether we are in the Champions League, Europa League or nowhere near that.‘And we’ll have a very clear plan of what we want to do and depending where we are we have to act like this.’MORE: Shkodran Mustafi and Cedric Soares return to training ahead of Arsenal vs West HamMORE: Lee Dixon slams Arsenal team who are ‘not good enough’ to succeedFollow Metro Sport across our social channels, on Facebook, Twitter and Instagram. For more stories like this, check our sport page. Soares is recovering from a knee problem (Picture: Getty)Cedric Soares insists he is nearing full fitness as Arsenal fans wait for the loan signing to make his debut for the club.The full-back was one of two signings for Arsenal in January, but arrived from Southampton carrying a knee injury.Arteta is keen to have a fully fit squad and Soares said on social media he is almost ready to return to action.‘Working hard with the guys and getting closer to full fitness,’ he said.ADVERTISEMENTSoares was training with the first-team this week, but was wearing strapping on his left leg as he continues his recovery.Defenders Shkodran Mustafi and Kieran Tierney were also back in training in further boosts for Arteta’s squad. Lucas Torreira, on the other hand, faces a spell on the sidelines after going off injured in the FA Cup win over Portsmouth.AdvertisementAdvertisementThe midfielder fractured his ankle and is there is not yet a date for his return.Arsenal welcome West Ham to the Emirates on Saturday hoping a win will see them climb up the Premier League table.More: FootballRio Ferdinand urges Ole Gunnar Solskjaer to drop Manchester United starChelsea defender Fikayo Tomori reveals why he made U-turn over transfer deadline day moveMikel Arteta rates Thomas Partey’s chances of making his Arsenal debut vs Man CityThe Gunners are tenth and currently eight behinds off the final Champions League spot.Arsenal were knocked out of the Europa League and Arteta admitted missing out on Champions League football will have a huge effect on the club’s transfer business in the summer.‘The damage caused by the club not being in the Champions League for the third season is really big,’ Arteta said. Advertisement Arsenal defender Cedric Soares issues fitness update Advertisementlast_img read more

MLB hot stove: Bryce Harper not a good fit for Yankees, GM Brian Cashman says

first_imgCashman said the Yankees already have six outfielders and playing Harper at first base “isn’t realistic,” according to MLB.com.Brian Cashman indicated that Bryce Harper isn’t a fit for the #Yankees. Said the team already has six outfielders and that playing Harper at first base isn’t realistic.— Bryan Hoch (@BryanHoch) December 10, 2018Cashman said that at no point this winter did he talk about getting an outfielder. “The Harper stuff, I’m surprised you’re still asking.”— Bryan Hoch (@BryanHoch) December 10, 2018The 26-year-old star slashed .249/.393/.496 with 34 home runs and 100 RBIs in 159 games with the Nationals in 2018. Related News MLB trade rumors: Yankees still discussing dealing starter Sonny Gray to Padres MLB hot stove: Yankees will reportedly meet with Manny Machado, not willing to spend $300M for him Harper has spent all seven of his MLB seasons with Washington. He is a six-time All-Star and won the MVP award in 2015.center_img The Yankees appear unlikely to sign Bryce Harper.New York has already traded for starter James Paxton and it is expected to continue to be active this offseason. Yankees general manager Brian Cashman told reporters Monday the team is not looking to add Harper because he isn’t a good fit for the team. The Yankees, however, have already had discussions with star free agent infielder Manny Machado’s agent, Cashman said.  Cashman said that he has talked more than once with Manny Machado’s agent, Dan Lozano.— Bryan Hoch (@BryanHoch) December 10, 2018New York is also working to deal starter Sonny Gray before the 2019 season begins, Cashman said in November.last_img read more

Shooting in St. Augustine

first_imgPolice are investigating a shooting that occurred on Riberia Street in St. Augustine, Tuesday morning. It is reported that a victim has been airlifted to a local hospital.There is no suspect in custody.The extent of injuries has not been released at this time.Police are at the scene now.last_img

Leafs deal Bolding, Selby to Sicamous for futures

first_imgThere’s no way a hockey team can keep four goalies happy during practice let alone during the regular season of a junior hockey league season.So the Nelson Leafs coaching staff did its best to solve the problem by sending netminder Josh Bolding and forward Spencer Selby to the Sicamous Eagles in a Kootenay International Junior Hockey League deal Tuesday.The Leafs, in return, receive future considerations.The deal leaves Nelson with three goalies in camp — Devin Allen and Ben Kelsch on the playing roster and Jason Sandhu on the injury list.Bolding, 18, came to Nelson as a late Junior A cut.The 6’5”, 190-pound native of Calgary played two games for Nelson, finishing with a 1-1 record after backstopping the Leafs to a 5-3 win last Friday over Grand Forks.Selby, also 18, played nine games for Nelson at forward, finishing with two assists.“I think we’ve got three goaltenders that could be starters and what combination we’re going to go with is something that as a coaching staff we’re going to decide,” said Leafs coach Mario DiBella following Saturday’s 4-1 victory over Spokane. “The requirement of getting someone else into camp was based on (Jason) Sandhu going down with injury, and not knowing how serious that injury was. Certainly we felt both Bolding and Allen we brought in to tryout have responded well.”Leafs continue to tinker with the roster, adding defenceman Noah Looman this week.Looman comes to Nelson from Yorkton Terriers of the Saskatchewan Junior Hockey League.DiBella is also hoping for another cut from the BC Hockey League.Nelson, currently riding a three-game winning streak, is back in action Friday when the Leafs travel to Fruitvale to face the Nitehawks.Friday’s encounter makes the fourth time this season the teams have played in Beaver Valley.Saturday, Nelson sees its first action against Eddie Mountain opposition when Columbia Valley visits the NDCC Arena.Game time is 7 p.m.The game is a salute to Breast Cancer Month. Special guest is Galena Rose Pal and her daughter Snow.The Heritage City has been rallying behind the Nelson woman after the mother of one was diagnosed with a serious form of breast cancer.Pal and her daughter will be on hand to perform the puck drop during the opening faceoff.last_img read more